Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business DailyRegeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.
The post Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms appeared first on Investor…